Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th:
Zynex, Inc. (ZYXI - Free Report) : This company that designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.3% over the last 60 days.
Zynex’s shares gained 84.1% over the last one month compared with the S&P 500 growth 15.7%. The company possesses a Momentum Score of A.
Pluralsight, Inc. : This company that provides a technology skill development solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.4% over the last 60 days.
Pluralsight’s shares gained 58.5% over the last one month. The company possesses a Momentum Score of A.
Gold Fields Limited (GFI - Free Report) : This company that operates as a gold producer with reserves and resources has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.
Gold Fields’ shares gained 47.4% over the last one month. The company possesses a Momentum Score of A.
Axovant Gene Therapies Ltd. : This clinical-stage gene therapy company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.
Axovant Gene Therapies’ shares gained 28.1% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th:
Zynex, Inc. (ZYXI - Free Report) : This company that designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.3% over the last 60 days.
Zynex’s shares gained 84.1% over the last one month compared with the S&P 500 growth 15.7%. The company possesses a Momentum Score of A.
Pluralsight, Inc. : This company that provides a technology skill development solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.4% over the last 60 days.
Pluralsight’s shares gained 58.5% over the last one month. The company possesses a Momentum Score of A.
Gold Fields Limited (GFI - Free Report) : This company that operates as a gold producer with reserves and resources has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.
Gold Fields’ shares gained 47.4% over the last one month. The company possesses a Momentum Score of A.
Axovant Gene Therapies Ltd. : This clinical-stage gene therapy company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.
Axovant Gene Therapies’ shares gained 28.1% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ZYXI - FREE
Get the latest research report on GFI - FREE